DOCSLIB.ORG

Metrochem API Private Limited

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Metrochem API Private Limited Metrochem API Private Limited USDMF/ Sr No APIs CEP Submission Date Status Numbers 1 Acotiamide Hydrochloride 2 Antazoline Hydrochloride CEP 2020-060 Monday, February 10, 2020 3 Antazoline Phosphate USDMF 34330 Monday, February 10, 2020 4 Apixaban 5 Azilsartan Medoxomil Potassium 6 Baloxavir Marboxil Product Under Validation 7 Bempedoic acid Product Under Validation 8 Benznidazole 9 Bepotastine Besilate 10 Bilastine 11 Cinitapride Hydrogen Tartrate 12 Clopidogrel Bisulphate (form I & II) USDMF 34334 Wednesday, February 5, 2020 13 Dabigatran Etexilate Mesylate 14 Dexketoprofen Trometamol USDMF 34732 Saturday, March 21, 2020 15 Dexlansoprazole 16 Dexrabeprazole Sodium 17 Dimetindene maleate 18 Elagolix Sodium Product Under Validation 19 Elobixbat Product Under Validation 20 Esomeprazole Magnesium 21 Etoricoxib USDMF 34537 Saturday, February 22, 2020 22 Febuxostat 23 Fenticonazole Nitrate 24 Flecainide Acetate 25 Fosfomycin Sodium Product Under Validation 26 Fosfomycin Tromethamine Product Under Validation 27 Fosravuconazole Product Under Validation 28 Ilaprazole 29 Isavuconazonium sulfate 30 Itraconazole 31 Ivabradine Product Under Validation 32 Lansoprazole 33 Lanthanum carbonate 34 Lercanidipine Product Under Validation Note: None of the products will be supplied to the countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purpose only. However, the final responsibility exclusively lies with the buyer. Metrochem API Private Limited USDMF/ Sr No APIs CEP Submission Date Status Numbers 35 Levocetirizine Di HCL 36 Levomilnacipran Hcl Product Under Validation 37 Lifitegrast Product Under Validation 38 Loxoprofen sodium Product Under Validation 39 Lurasidone HCl 40 Migalastat Product Under Validation 41 Mirabegron 42 Montelukast Sodium 43 Omeprazole 44 Oxiconazole Nitrate 45 Ozenoxacin 46 Pantoprazole sodium sesquihydrate 47 Posaconazole 48 Prucalopride Succinate 49 Rabeprazole sodium 50 Ranolazine Product Under Validation 51 S - Pantoprazole Sodium 52 Saxagliptin Hcl 53 Silodosin USDMF 34538 Tuesday, March 10, 2020 54 Solifenacin Succinate 55 Stiripentol Product Under Validation 56 Tafenoquine Succinate Product Under Validation 57 Tedizolid Phosphate 58 Tenatoprazole Sodium 59 Teneligliptin 60 Tofacitinib citrate 61 Upadacitinib tartrate Product Under Validation 62 Vigabatrin 63 Vonoprazan 64 Dabigatran 65 Dabigatran Etexilate 66 Fingolimod 67 Imeglimin Hydrochloride 68 Imeglimin Product Under Validation 69 Tranexemic Acid Product Under Validation 70 Vildagliptin 71 Bilastine Product Under Validation 72 Fosfomycin 73 Topiroxostat Product Under Validation 74 Edoxaban Note: None of the products will be supplied to the countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purpose only. However, the final responsibility exclusively lies with the buyer. Metrochem API Private Limited USDMF/ Sr No APIs CEP Submission Date Status Numbers 75 Duloxetine 76 Crisaborole Product Under Validation 77 Eltrombopag 78 Relugolix 79 Alogliptin Benzoate 80 Azilsartan 81 Canagliflozin Hemihydrate 82 Dapagliflozin Propanediol Monohydrate 83 Edoxaban Tosylate Product Under Validation 84 Empagliflozin 85 Ertugliflozin L-PGA 86 Favipiravir 87 Garenoxacin 88 Gabapentin 89 Rimegepant 90 Lasmiditan 91 Vortioxetine 92 Lacosamide 93 Efinaconazole Product Under Validation 94 Fosfomycin Calcium Product Under Validation 95 Garenoxacin Mesylate Product Under Validation 96 Omecamtiv Mecarbil Product Under Validation Note: None of the products will be supplied to the countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purpose only. However, the final responsibility exclusively lies with the buyer. Pellets Sr No Products Remarks 7.5%, 8.5%, 10%, 12.5%, 15%, 20%, 25%, etc., 1 Omeprazole Also Available as Blended / Combination Pellets as Omeprazole (EC) & Domperidone (SR) 8.5%, 10%, 15%, 22.5%, 23.5%, 26.67% etc; Esomeprazole Dihydrate Pellets - 8.5%, 10%, 15%, 22.5% etc., 2 Esomeprazole Magnesium Also Available as Blended / Combination Pellets as Esomeprazole Magnesium (EC) & Domperidone (SR) 7.5%, 8.5%, 13.33%, 15%, 17%, 20%, 22.5% etc., 3 Rabeprazole Also Available as Blended / Combination Pellets as Rabeprazole Sodium (EC) & Domperidone (SR) 15%, 21%, 22.5% etc., S-Pantoprazole Pellets - 20% etc., 4 Pantoprazole Also Available as Blended / Combination Pellets as Pantoprazole Sodium (EC) & Domperidone IR & SR 5 Dexrabeprazole 8.5%, 10%, 15% etc., 6 Dexlansoprazole 8.5%, 10% etc., 10%, 20%, 30%, 40%; Also Available as in Blended / Combination Pellets 7 Domperidone with Pantoprazole Sodium, Rabeprazole Sodium & Esomeprazole Magnesium 8 Itopride HCl (SR) 9 Itraconazole 20%, 22% 10 Aspirin 30%, 50%, 60% 11 Clopidogrel 30%, 50%, 60% 12 Dabigatran Etexilate Mesylate 40% 13 Dabigatran 14 Silodosin 2%, 4% (SR) - 0.12%, 0.2%, Also Available as Blended/Combination Pellets as 15 Tamsulosin Tamsulosin & Dutasteride 16 Levosulpiride 50% 17 Duloxetine EC 18 Duloxetine 19 Levomilnacipran HCl 20 Flurbiprofen 21 Mesalamine 0.5%; Also Available as Blended/Combination Pellets as Tamsulosin & 22 Dutasteride Dutasteride 23 Lansoprazole 6%, 7.5%, 8.5%, 10%, 10.5%, 11%, 11.2%, 11.5%, 12%, 14% etc. 24 Tenatoprazole 25 Cinitapride 26 Diclofenac Sodium (SR) - 40%, 50% 27 Diclofenac Potassium (SR) - 40%, 50% 28 Ketoprofen (SR) - 70% 29 Terbinafine Hydrochloride 30 Venlafaxine HCl (SR) - 25%, 33%, 35% 31 Fluoxetine Hydrochloride 70% 32 Diltiazem Hydrochloride 50% 33 Metoprolol Succinate 50%, 60% Note: None of the products will be supplied to the countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purpose only. However, the final responsibility exclusively lies with the buyer. Pellets Sr No Products Remarks 34 Nicardipine 35 Telmisartan 36 Indomethacin 20% 37 Donepezil 38 Galantamine 39 Atorvastatin 40 Fenofibrate 41 Ferrous Sulphate 42 Mebeverine (SR) - 20%, 40% 43 Orlistat 0.5 44 Aprepitant 45 Budesonide 46 Ciprofloxacin 47 Pregabalin 0.5 48 Theophylline 0.7 49 Tizanidine HCI (SR) - 3.5% 50 Oxeladin 51 Mesalamine 52 Tacrolimus 53 Tramadol Hydrochloride 54 Tolterodine Tartrate 0.02 Note: None of the products will be supplied to the countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purpose only. However, the final responsibility exclusively lies with the buyer..
Load more

Recommended publications
  • Oral Antifungal Agent Nailin® Capsules 100Mg Approved in Japan
    FOR IMMEDIATE RELEASE January 19, 2018 Sato Pharmaceutical Co., Ltd. Eisai Co., Ltd. ORAL ANTIFUNGAL AGENT NAILIN® CAPSULES 100MG APPROVED IN JAPAN Sato Pharmaceutical Co., Ltd. (Headquarters: Tokyo, President and CEO: Seiichi Sato, “Sato Pharma”) obtained marketing and manufacturing approval for the oral antifungal agent NAILIN® Capsules 100mg containing the active ingredient fosravuconazole L-lysine ethanolate (“fosravuconazole”) for the treatment of onychomycosis in Japan on January 19, 2018. Sato Pharma and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) are jointly providing information on its proper use. Fosravuconazole, the active ingredient of NAILIN® Capsules 100mg, is a new triazole class oral antifungal component discovered by Eisai. Sato Pharma conducted a Phase III clinical study of the agent in patients with onychomycosis in Japan, and after confirming efficacy and safety of the agent in the study, Sato Pharma applied for marketing and manufacturing authorization in January 2017. Onychomycosis affects 1 in every 10 Japanese people, and there are an estimated approximately 11 million sufferers in Japan. With Sato Pharma now having obtained marketing and manufacturing approval for NAILIN® Capsules 100mg, as an oral treatment for onychomycosis, this is the first new treatment for the disease in approximately 20 years. By providing NAILIN® Capsules 100mg as a new option for the treatment of onychomycosis, Sato Pharma and Eisai will strive to fulfil the needs of onychomycosis patients and healthcare professionals.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • R&D Model & Portfolio
    R&D MODEL & PORTFOLIO ADAPTED TREATMENTS FOR THE BENEFIT OF NEGLECTED PATIENTS The R&D strategies developed by DNDi since its inception aim to Phase II trials as a potential single- address the immediate needs of patients by improving existing dose oral treatment and is the first therapeutic options in the short term, whilst undertaking longer molecule to arise from DNDi’s lead term research to identify and develop entirely new compounds optimization programme. which will be valuable adapted tools, particularly for elimination targets set by the World Health Organization. Although not Leishmaniasis is a complex family necessarily breakthrough medicines, six new treatments have of diseases, and the identification been delivered to date as a result of the short-term strategy, of new compounds has proved which have brought significant benefits to patients. challenging. Compound libraries from a variety of sources have been screened and, despite the inevitable The year 2015 has been a turning are orally available compounds for loss of compounds to attrition, NCEs point for DNDi, as long-term systemic use. The most clinically from the nitroimidazole, oxaborole, investments have now filled the advanced of these are for sleeping and aminopyrazole chemical drug development pipeline with sickness: fexinidazole, which was families are undergoing lead thirteen new chemical entities identified from compound mining optimization to combat Leishmania (NCEs) included by the end of the and is a ten day oral treatment, infections, with the nitroimidazole year, the vast majority of which and SCYX-7158, which is entering VL-0690 selected to go forward to 14 › DNDi Annual Report 2015 R&D MODEL & PORTFOLIO pre-clinical development in 2015.
    [Show full text]
  • Minutes of the 612Thmeeting Ofthe State
    Minutes of the 612thmeeting ofthe State Level Expert Appraisal Committee(SEAC) held on 18/03/2020 at Committee Room, Gujarat Pollution Control Board, Sector 10A,Gandhinagar. The 612thmeeting of the State Level Expert Appraisal Committee (SEAC) was held on 18th March 2020 at Committee Room, Gujarat Pollution Control Board, Sector 10A, Gandhinagar. Following members attended the meeting: 1. Dr. Dinesh Misra, Chairman, SEAC 2. Shri S. C. Srivastav, Vice Chairman, SEAC 3. Shri V. N. Patel, Member, SEAC 4. Shri. R. J. Shah, Member, SEAC 5. Shri A. K. Muley, Member, SEAC 6. Dr. V. K. Jain, Member, SEAC 7. Shri A. V. Shah, Secretary, SEAC The regular agenda of Appraisal, Screening & Scoping/ToR / EC – Reconsiderationcases were taken up. The Committee considered the applications made by project proponents, additional details submitted as required by the SEAC/SEIAA and details furnished in the Form-1, PFR, EIA-EMP reports. Proposal No. Name and Address of the Unit Remarks 1 SIA/GJ/IND2/27657/2018 M/s. Lincoln Pharmaceutical Limited Appraisal Block No. 176 (old Block No. 95/5-B), At – Khatraj, Ta. Kalol, Dist. Gandhinagar. Category of the unit: 5(f) Project status: New Project proponent (PP) has submitted online application vide no. SIA/GJ/IND2/27657/2018 on dated 05/11/2019 for obtaining Environmental Clearance. The SEAC had recommended TOR to SEIAA and SEIAA issued TOR to PP vide their letter dated 30/10/2018. Project proponent has submitted EIA Report prepared by M/s. Bhagwati Enviro Care Pvt. Ltd., Ahmedabad based on the TOR issued by SEIAA. Public Hearing of the Project was conducted by Gujarat Pollution Control Board at Project Site of M/s.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Fosravuconazole L-Lysine Ethanolate | Medchemexpress
    Inhibitors Product Data Sheet Fosravuconazole L-lysine ethanolate • Agonists Cat. No.: HY-16779B CAS No.: 914361-45-8 Molecular Formula: C₃₁H₄₀F₂N₇O₈PS • Molecular Weight: 739.73 Screening Libraries Target: Fungal; Parasite Pathway: Anti-infection Storage: Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month SOLVENT & SOLUBILITY In Vitro DMSO : 50 mg/mL (67.59 mM; Need ultrasonic) H2O : < 0.1 mg/mL (ultrasonic) (insoluble) Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 1.3518 mL 6.7592 mL 13.5184 mL Stock Solutions 5 mM 0.2704 mL 1.3518 mL 2.7037 mL 10 mM 0.1352 mL 0.6759 mL 1.3518 mL Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (3.38 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (3.38 mM); Clear solution BIOLOGICAL ACTIVITY Description Fosravuconazole L-lysine ethanolate (BMS-379224 L-lysine ethanolate), a prodrug of Ravuconazole, is an orally active broad spectrum antifungal agent. Fosravuconazole L-lysine ethanolate can be used for candidiasis, onychomycosis and parasitemia research[1][2][3]. In Vitro Fosravuconazole has potent in vitro antifungal activity against a wide range of fungal species, including Candida, Aspergillus , and Trichophyton species[1]. MCE has not independently confirmed the accuracy of these methods.
    [Show full text]
  • Surveillance of Antifungal Use in Japan Oral Medicine + Injection Change in Antifungal Use for All of Japan by Rout of Administration 1
    Surveillance of antifungal use in Japan Oral medicine + Injection Change in antifungal use for all of Japan by rout of administration 1 0.9 / day 0.8 0.7 0.6 0.5 0.4 Dose / inhabitants / 1,000 Dose 0.3 Daily 0.2 0.1 Defined 0 2013 2014 2015 2016 2017 2018 2019 Injection注射薬 内服薬Oral medicine(テルビナフィン・ホスラブコナゾールを除く (except for terbinafine and fosravuconazole) ) ホスラブコナゾールFosravuconazole テルビナフィンTerbinafine Oral medicine Change in antifungal use (oral medicine) for all of Japan 1 0.9 / day 0.8 0.7 0.6 0.5 0.4 Dose / inhabitants / 1,000 Dose 0.3 Daily 0.2 0.1 Defined 0 2013 2014 2015 2016 2017 2018 2019 フルシトシンFlucytosine ボリコナゾールVoriconazole イトラコナゾールItraconazole フルコナゾールFluconazole ホスラブコナゾールFosravuconazole テルビナフィンTerbinafine Injection Change in antifungal use (injection) for all of Japan 0.035 / day 0.03 0.025 0.02 0.015 Dose / inhabitants / 1,000 Dose 0.01 Daily 0.005 Defined 0 2013 2014 2015 2016 2017 2018 2019 Amphotericinアムホテリシン BB ミコナゾールMiconazole フルコナゾールFluconazole イトラコナゾールItraconazole Voriconazoleボリコナゾール Caspofunginカスポファンギン ミカファンギンMicafungin 〇The data are calculated from claims registered in the NDB. The data do not always reflect the precise antibiotic use because the data of patients who receive publicly funded health care are not always included. The numerical values are different from those of the surveillance of antibiotic sales (http://amrcrc.ncgm.go.jp/surveillance/020/20190902163931.html) due to the different data source. 〇The figures indicate drug utilization standardized by defined daily dose (DDD) per population and drug, called DID (DDDs/1,000 inhabitants/day) (Reference:https://www.whocc.no/atc_ddd_index/ ).
    [Show full text]
  • Mining Sudanese Medicinal Plants for Natural Compounds Against Malaria and Neglected Tropical Diseases
    Mining Sudanese Medicinal Plants for Natural Compounds against Malaria and Neglected Tropical Diseases INAUGURALDISSERTATION zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Abdelhalim Babiker Mohamed Mahmoud aus dem Sudan Basel, 2020 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Pascal Mӓser Prof. Dr. Thomas J. Schmidt Basel, den 23.06.2020 Prof. Dr. Martin Spiess Dekan To my father Who taught me that perseverance and hard work always pays off. May your inspiring soul rest in peace. Table of Contents Acknowledgment ...................................................................................................................................................... I Abbreviations .......................................................................................................................................................... III Summary .................................................................................................................................................................... V 1. INTRODUCTION: Neglected Tropical Diseases, Drug Discovery, and the Sudan .................... 1 1.1 Neglected Tropical Diseases ............................................................................................................................ 3 1.1.1 NTDs and Sudan .........................................................................................................................................
    [Show full text]
  • Frontiers in Dermatology and Venereology - a Series of Theme Issues in Relation to the 100-Year Anniversary of Actadv
    ISSN 0001-5555 ActaDV Volume 100 2020 Theme issue ADVANCES IN DERMATOLOGY AND VENEREOLOGY A Non-profit International Journal for Interdisciplinary Skin Research, Clinical and Experimental Dermatology and Sexually Transmitted Diseases Frontiers in Dermatology and Venereology - A series of theme issues in relation to the 100-year anniversary of ActaDV Official Journal of - European Society for Dermatology and Psychiatry Affiliated with - The International Forum for the Study of Itch Immediate Open Access Acta Dermato-Venereologica www.medicaljournals.se/adv ACTA DERMATO-VENEREOLOGICA The journal was founded in 1920 by Professor Johan Almkvist. Since 1969 ownership has been vested in the Society for Publication of Acta Dermato-Venereologica, a non-profit organization. Since 2006 the journal is published online, independently without a commercial publisher. (For further information please see the journal’s website https://www. medicaljournals.se/acta) ActaDV is a journal for clinical and experimental research in the field of dermatology and venereology and publishes high- quality papers in English dealing with new observations on basic dermatological and venereological research, as well as clinical investigations. Each volume also features a number of review articles in special areas, as well as Correspondence to the Editor to stimulate debate. New books are also reviewed. The journal has rapid publication times. Editor-in-Chief: Olle Larkö, MD, PhD, Gothenburg Former Editors: Johan Almkvist 1920–1935 Deputy Editors: Sven Hellerström 1935–1969
    [Show full text]
  • A Road Map for Neglected Tropical Diseases 2021–2030
    Buruli ulcer Chagas disease Dengue and chikungunya Ending the neglect to Dracunculiasis attain the Sustainable Echinococcosis Development Goals Foodborne trematodiases A road map for neglected Human African trypanosomiasis tropical diseases 2021–2030 Leishmaniasis Leprosy Lymphatic filariasis Mycetoma, chromoblastomycosis and other deep mycoses Onchocerciasis Rabies Scabies and other ectoparasitoses Schistosomiasis Soil-transmitted helminthiases Snakebite envenoming Taeniasis and cysticercosis Trachoma Yaws SECTION 01: CONTEXT AND PURPOSE OF THE ROAD MAP 01 Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030 ISBN 978-92-4-001035-2 (electronic version) ISBN 978-92-4-001036-9 (print version) © World Health Organization 2020 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.
    [Show full text]
  • The Activity of 2,3-Dimethylquinoxaline Against Madurella Mycetomatis
    American Journal of www.biomedgrid.com Biomedical Science & Research ISSN: 2642-1747 --------------------------------------------------------------------------------------------------------------------------------- Research Article Copy Right@ Abdelbagi Alfadil The Activity of 2,3-Dimethylquinoxaline against Madurella mycetomatis Abdelbagi Alfadil1*, Ahmed Shaker Ali2, Hamoud Alsamhan2,3, Huda Alkreathy2, Asif Jiman-Fa- tani1 and Hind Abdulmajed1 1Department of Microbiology and Medical Parasitology, King Abdulaziz University, Saudi Arabia 2Department of Pharmacology, King Abdulaziz University, Saudi Arabia 3College of Pharmacy, King Saud bin Abdulaziz University for Health Science, Saudi Arabia *Corresponding author: Abdelbagi Alfadil Mousa, Department of Microbiology and Medical Parasitology, College of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. To Cite This Article: Abdelbagi A, A Shaker Ali, H Alsamhan, H Alkreathy, A Jiman-Fatani. H Abdulmajed. The Activity of 2,3-Dimethylquinox- aline against Madurella mycetomatis. Am J Biomed Sci & Res. 2021 - 11(4). AJBSR.MS.ID.001654. DOI: 10.34297/AJBSR.2021.11.001654. Received: January 06, 2021; Published: January 18, 2021 Abstract Objective: Madurella mycetomatis is the most prevalent causative species of the eumycetoma, a chronic progressive neglected tropical disabling treatment is challenging, requires prolonged therapy, resulting in low cure rates and a high incidence of recurrence. Screening new compounds for antifungalinfectious diseaseactivity ofagainst the subcutaneous Madurella mycetomatis tissue. It carries is needed. a significant social and economic burden to the endemic areas. Unfortunately, the available Design: In vitro: the susceptibility of a Madurella mycetomatis of 2,3-dimethylquinoxaline 1% topical gel against the same strain was evaluated in the BALB/c mouse eumycetoma model (n=6; 6-8 weeks old). isolate toward the 2,3-dimethylquinoxaline was determined. In vivo: the efficacy Results: 2,3-Dimethylquinoxaline inhibited the growth of Madurella mycetomatis at MIC 312 µg/ml (1.9 mM).
    [Show full text]